Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression

Xiaoxuan Sun1, Xiaoke Feng1,2, Wenfeng Tan1, Na Lin1, Minhui Hua1, Yu Wei1, Fang Wang3, Ningli Li4 & Miaojia Zhang1

We previously reported adiponectin (AD) is highly expressed in the inflamed synovial joint tissue and correlates closely with progressive bone erosion in Rheumatoid arthritis (RA) patients. Here, we investigate the role of adiponectin in regulating Th17 response and the expression of receptor activator of nuclear factor-κB ligand (RANKL) in mice with CIA mice by intraarticularly injection of adiponectin into knee joints on day 17, day 20 and day 23 post first collagen immunization. The increased adiponectin expression was found in inflamed joint tissue of collagen-induced arthritis (CIA) mice. Adiponectin injection resulted in an earlier onset of arthritis, an aggravated arthritic progression, more severe synovial hyperplasia, bone erosion and osteoporosis in CIA mice. CD4+IL-17+ Th17 cells, IL-17 mRNA and RANKL mRNA expression were markedly increased in the joint tissue of adiponectin treated CIA mice. Moreover, adiponectin treatment markedly enhanced Th17 cell generation from naive CD4+ T cells in vitro, which accompanied by the high expression of Th17 transcription factor ROR-γt, and Th17 cytokine genes included IL-22 and IL-23. This study reveals a novel effect of adiponectin in exacerbating CIA progression by enhancing Th17 cell response and RANKL expression.

Rheumatoid arthritis (RA) is a common rheumatic disease that is characterized by chronic inflammation, joint destruction and progressive disability1. Despite intensive efforts in the development of new therapies to prevent the disease progress in RA2, a proportion of patients still failed to current synthetic or biological disease-modifying anti-rheumatic drugs (DMARDs) therapy3. Therefore, it is still a critical challenge to find novel targets for RA therapy.

Although the precise etiology of RA still remains elusive4, substantial evidence has suggested that T cells, B cells and the complex interaction of multiple pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1 and IL-17, play a critical role in the pathophysiology of RA4,5. Therapies targeting against TNF-α, IL-1 and IL-6 have demonstrated the favorable clinical outcomes in patients with RA, highlighting the critical role of pro-inflammatory cytokines in RA pathophysiology.

Adipose tissue or the adipocytes in joints have long been considered as none-bioactive cells and only devoted to energy storage. During recent years, there is growing evidence that adipokines produced by white adipose tissue including adiponectin (AD), leptin, visfatin and resistin play an important role in
regulating immune and inflammatory processes. AD is the most abundant adipokine, being present at concentrations of 5–30 μg/mL in circulation. It is produced prevalently by adipose tissues, but is also secreted by skeletal muscles, cardiac myocytes, and endothelial cells. AD exerts its functions by acting on its receptors: adiponectin receptor 1 (AdipoR1) and adiponectin receptor 2 (AdipoR2)⁹.

Our previous studies have demonstrated that AD is highly expressed in the inflamed synovial joint tissue and correlates closely with progressive bone erosion in RA patients. Moreover, local levels of AD are positively correlated with IL-6 in RA synovial fluids. Stimulation of RA synoviocytes with AD could trigger a high expression of IL-6 and monocyte chemotactic protein-1 (MCP-1)¹⁰, suggesting that AD might participate in the local chronic inflammation and bone erosion in RA. Emerging evidence reveals that AD could increase the migration of synovial fibroblasts (SFs) and lymphocytes in RA¹¹, indicating a role of AD involved in the synovitis of RA. Interestingly, recent clinical studies have suggested that serum levels of AD are linked to the radiographic progression in RA¹², implying that AD might participate in bone erosion in RA.

T cells that preferentially produce IL-17 are named T helper cell 17 (Th17 cell), which have been shown to play a key role in orchestrating inflammatory response. In patients with RA, secretion of IL-17 by Th17 cell was found to induce IL-6 in cultured synoviocytes¹³. Besides the production of matrix metalloproteases, IL-17 can also destroy extracellular matrix and cause bone resorption¹⁴. In addition, IL-17 could stimulate osteoblasts to express the receptor activator of nuclear factor-κB (RANK) ligand (RANKL), which are critically involved in osteoporosis and bone erosion¹⁵.

Osteoclasts, formed by fusion of mononuclear precursors of the monocyte/macrophage, are the cell type ultimately responsible for bone destruction in RA. The development, activity, and survival of osteoclasts require an essential osteoclastogenic mediator: RANKL¹⁶. RANKL, a membrane-residing protein on osteoclasts, interacts with RANK, inducing marrow macrophages differentiation into osteoclasts¹⁷. RANKL exerts its functions by binding to its unique receptor RANK, and osteoprotegerin (OPG) acts as its natural decoy receptor by blocking the RANK/RANKL interaction. Mice lacking OPG exhibit severe osteoporosis and bone erosion, implicating the importance of RANKL/OPG balance for maintaining osteoclast homeostasis¹⁸.

Recent studies including our findings have indicated that AD is involved in bone erosion in RA. However, the underlying mechanisms remain unclear. The strong link between RANKL, IL-17 and bone erosion prompted us to examine whether AD could affect Th17 differentiation and RANKL expression and thereby accelerate bone erosion in RA. In the present study, we determined the effect of AD on modulating Th17 cell response and RANKL expression in vitro and in mice suffering from collagen-induced arthritis (CIA). We revealed a previously unrecognized role of AD in RA in current study.

Results

Local AD, IL-17 and RANKL levels are increased during CIA development. To determine the role of AD in the pathogenesis of autoimmune arthritis, we first examined the expression of AD in joint tissue from CIA mice. Joint tissues from DBA/1J and CIA mice on both day 35 (at the early phase of arthritis) and day 45 (at peak phase of arthritis) post the 1st immunization were analyzed by immunohistochemical staining for AD expression. As shown in Fig. 1A-B, the number of AD positive cells was substantially increased in the inflamed joint tissue of CIA mice on both day 35 and day 45. Consistent with the results of immunohistochemical staining, markedly elevated levels of AD transcripts were detected in joint tissue of CIA mice by real-time polymerase chain reaction (PCR) analysis when compared with control mice (Fig. 1C). Moreover, the expression of both IL-17 and RANKL were significantly higher on day 35 than day 45 post the 1st immunization during CIA development (Fig. 1D,E). These data implied a positive correlation of locally increased AD with IL-17 and RANKL expression during CIA progression.

Local AD injection aggravates CIA mice arthritic development and bone erosion. Next, we examined whether AD could enhance CIA progression and bone erosion by local injection of AD into the knee joint in mice with CIA. A dose of 10 μg AD was intraarticularly injected into the knee joint of CIA mice consecutively on days 17, 20 and 23 post the 1st type II collagen (CII) immunization of DBA/1J mice (Fig. 2A). As shown in Fig. B–D, AD-treated CIA mice exhibited an earlier onset of arthritis and higher arthritis scores than the control CIA mice treated with phosphate buffered saline (PBS). Histopathological analysis indicated that more pronounced synovial hyperplasia, cartilage damage and bone erosion were observed in AD-treated CIA mice compared to the control CIA mice (Fig. 2E,F). Micro computed tomography (Micro-CT) examination showed that more severe bone erosion was detected in the periarticular bone of paws and ankles from AD-treated CIA mice (Fig. 3A). Moreover, AD-treated CIA mice showed statistically significant decrease in trabecular number and trabecular bone mineral density (BMD) in both femur and tibia compared with PBS-treated group (Fig. 3B,C). The cortical bone mineral density in the tibia was also reduced in AD-treated CIA mice compared to PBS-treated CIA mice, but did not reach statistical significance (Fig. 3D). Taken together, the locally increased levels of AD in the joint of CIA mice could directly exacerbate the arthritis signs, synovial inflammation and joint damage in CIA mice, suggesting that AD might participate in disease progression in CIA mice.

Increased Th17 cells and its relative cytokines in the joint tissue of AD-treated CIA mice. Since IL-17 plays a critical role in bone erosion in RA patient and murine arthritis, we sought to determine
whether AD could affect IL-17 and Th17 cells expression in the joint tissue of CIA mice. Flow cytometric analysis indicated CD4^+IL-17^+ Th17 cell was an approximate 1.5-fold expansion in joint tissue of AD-treated CIA mice at day 45 (Fig. A,B) compare to untreated CIA mice. Consistent with the flow cytometric data, real-time PCR analysis revealed that IL-17 expression showed a 10-fold increase on day 45 post the 1st immunization (Fig. 4C). We also analyzed the expression of IL-17 related factors including IL-22 and IL-23 messenger ribonucleic acid (mRNA) in joint tissues by real-time PCR. The expression of IL-22 and IL-23 in joint tissue were significantly up-regulated in CIA mice after AD injection (Fig. 4D,E). Collectively, these results indicated that AD might be involved in promoting Th17-mediated bone erosion.

Effect of AD on RANKL expression in joint tissue of CIA mice. Furthermore, we evaluated potential effect of AD on the expression of RANKL in CIA model. It was found that the expression levels of RANKL reached a peak level on day 45 post the 1st immunization in AD treated mice (Fig. 5C). Immunohistochemical analysis indicated a markedly elevated number of RANKL-expressing cells in the synovium of AD treated mice (Fig. 5A,B). Given most RANKL^+ cells appear to be synoviocytes, we then treated rheumatoid arthritis synovial fibroblasts (RASFs) with AD. A significantly increased levels of RANKL expression were found in AD-treated RASFs, as compared to untreated RASFs (Supplementary Fig 1. S1). Taken together, our data indicated a direct effect of AD on inducing RANKL expression.

AD promotes the differentiation of naïve T cells into Th17 cells in vitro. To further determine whether AD exerts a direct effect on promoting Th17 cell differentiation, naïve CD4^+ T cells from spleen of C57BL/6 mice were induced towards to Th17 differentiation in the presence or absence of AD for 3 days. The expression of both AdipoR1 and AdipoR2 transcripts could be detected in naïve CD4^+ T cells and in vitro-generated Th17 cells (Supplementary Fig 2. S2). Then, as shown in Fig. 6A,B, the frequencies of Th17 cells were significantly increased in a dose-dependent manner upon AD stimulation (Fig. 6A,B). The mRNA and protein levels of IL-17 in cultured cells and supernatants were also markedly elevated in AD treated T cells (Fig. 6C,D). The levels of retinoid-related orphan nuclear receptor-γt (ROR-γt), IL-21, IL-22 and IL-23 mRNA were determined by real-time PCR when naïve T cells were cultured in
the presence of different concentrations of AD for 72 hours. As indicated in Fig. 6E,H, the expression of ROR-\(\gamma\)t and IL-23 mRNA were enhanced in a dose dependent manner; however, we failed to detect the changes of IL-21 and IL-22 production in vitro (Fig. 6F,G). Together, these results demonstrated that AD could promote Th17 differentiation in vitro.

**Discussion**

RA is a systemic inflammatory disease that involves a hyperplasia of synovial tissues and a structural damage of cartilage and bone. In the present study, we first found that local AD, IL-17 and RANKL levels are increased during CIA development. Given IL-17 and RANKL are well established as the critical cytokines in mediating bone erosion in RA, here, we addressed whether AD could accelerate bone erosion in RA by prompting Th17 differentiation and enhancing RANKL expression. We have shown that intraarticular injection of AD into the knee joint of CIA can aggravate arthritic progression and bone erosion, which is accompanied by significantly increased number of Th17 cells and a high expression of RANKL in joint tissues. Furthermore, we have identified a previously unrecognized new role of AD in promoting the differentiation of naïve T cells into Th17 cells in vitro. Together, our results have demonstrated a critical role of AD in the pathogenesis of autoimmune arthritis.

The synovial tissue is recognized to be actively involved in governing the persistence of inflammatory disease. Cytokine production, particularly IL-17 that arises from synovial tissue, is central to the pathogenesis of bone erosion. IL-17, the major cytokine of Th17 cell, is an important inflammatory cytokine that induces production of prostaglandins, nitric oxide, cytokines and chemokines. IL-17 induces the production of IL-1 and TNF in macrophages and fibroblasts and is synergistic with IL-1 in the upregulation of inflammatory mediators released by synovial fibroblasts. At the same time, IL-17 blocks the function of regulatory T cell (Treg) and Th2 cell, and thereby inhibits local bone erosion as
well as systemic bone loss in CIA model of TNF-mediated arthritis, highlighting a critical role of IL-17 in RA pathogenesis. We find that the local increase of AD concentration can enhance the expression of Th17 and its transcription factor in joint tissue. Level of IL-17 mRNA is higher in AD-treated CIA mice especially on day 45 (a 10-fold increase). Moreover, we have also observed increased number of Th17 cells in joint tissues on day 45. These data have allowed us to propose that higher concentration of AD in inflamed joint is much more important in persistence of inflammatory microenvironment than occurrence of acute inflammatory responses.

Our data have clearly shown that AD can promote Th17 cell differentiation through upregulating the expression of ROR-γt, IL-22 and IL-23 expression. It is currently clear that ROR-γt is a unique transcription factor of Th17 by inducing the transcription of IL-17 gene in naive helper T cells. IL-22 is a cytokine that can induce epithelialcell proliferation and of antimicrobial proteins in keratinocytes. IL-23 is more important for Th17 expansion and stabilization. We have further defined a novel function of AD in promoting Th17 differentiation in vitro. Flow cytometry analysis revealed that the frequencies of Th17 cells were significantly increased with the stimulation of AD at a concentration of 10μg/ml. Notably, the expression of ROR-γt and IL-23 are up-regulated in a dose dependent manner. These results show that a higher expression of AD in inflamed joint is involved in modulating Th17 responses. These results indicate a novel role of AD in promoting Th17 cell differentiation. The biologic effect of AD is mediated through AdipoR that has been validated in previous studies. Further studies are needed to explore how AD acts on AdipoR to promote Th17 differentiation.

Remarkable progress has been made in recent years in the field of osteoclast research primarily due to the finding of the RANKL/RANK system. In the pathological condition of RA, proinflammatory cytokines produced by synovial fibroblasts in the inflamed joints can cause increased local joint RANKL expression. RANKL can stimulate osteoclast differentiation from hematopoietic precursor cells in vitro. It can also act on mature osteoclasts and activate the bone-resorbing activity and survival of the cells. RANKL binds to its receptor RANK, which induces intracellular signals including nuclear factor-κB (NF-κB) activation and c-Jun N-terminal kinase activation. The other important actor in this system is OPG, a soluble receptor of RANKL, which specifically binds to RANKL and inhibits RANKL activity by preventing its binding to RANK. In the present study, we find that the expression of RANKL in AD-treated CIA mice is significantly higher than that in PBS-treated CIA controls. We further observed significantly increased levels of RANKL expression in AD treated RASFs indicating a direct effect of
AD on inducing RANKL expression. We suggest that this type of regulation by AD has three potential mechanisms. First, it is possible that AD contributes to enhance the high expression of RANKL directly. In addition, the immunomodulatory role of AD might be another explanation for the regulation of RANKL in RA and arthritis models. Moreover, we have observed that local increase in AD directly modulated Th17 differentiation is accompanied by an increase of the production of IL-17 and IL-22, which are involved in regulating RANKL expression. These results demonstrate that AD is participated in the regulation of RANK/RANKL/OPG signaling pathway, promoting inflammation-induced osteoclastogenesis in CIA models and RA patients. Further studies are needed to explore whether AD acts to promote inflammation-induced osteoclast activation and bone erosion.

Study by Lee SW et al. has shown that AD could mitigate disease severity of CIA model. The data are conflicted with our results. In our experiments, globular AD was used to inject into the knee joint of CIA model; however, full-length AD was used in Lee’s study, which might be an impossible explanation of the opposite effects of AD on CIA between our study and Lee’s. There are mainly two isoforms of AD have been identified in circulation, with globular AD and full-length AD. A recent study by Klaus W Frommer et al have shown that different AD isoforms may induce diverging effects. After globular AD treatment, RASFs showed significantly increased expression of chemokines, proinflammatory cytokines and matrix metalloproteinases (MMPs), suggesting that globular AD might play a more potent proinflammatory role in RA pathogenesis as compared with full-length AD. Due to the intricate interactions of various immune cell types and complicated AD signal pathways involved in disease pathophysiology, further studies are need to determine the exact function of AD at the different stages of arthritis development in mice and RA patients.

Interestingly, Piccio L et al. have revealed that AD deficient mice could develop worse experimental autoimmune encephalomyelitis (EAE) with greater central nervous system (CNS) inflammation, more lymphocytes proliferation, higher amounts of interferon-γ (IFN-γ), IL-17, TNF-α and IL-6 than wild type (WT) mice. However, our data provide the solid evidence that the locally increased AD levels contributed to inflammation and bone erosion in CIA mice by enhancing Th17 response and prompting

Figure 4. Local AD injection increases Th17 and its transcription factors in joint tissue of CIA (A,B). The frequencies and total number of Th17 were analyzed by flow cytometry on day 45 post the 1st immunization (n = 3). (C). Relative expression of IL-17 in joint tissues was determined by real-time PCR on day 45 post the 1st immunization (n = 7). (D,E). Relative IL-22 and IL-23 mRNA levels in joint tissue of AD-treated and PBS-treated CIA mice on day 45 post the 1st immunization were measured by real-time PCR analysis (n = 7). All data were shown as mean ± SEM (*p < 0.05, **p < 0.01). Results are derived from 3 separate experiments.
RANKL expression. These contrasting results may suggest that systemic function and localized effect of AD in autoimmune pathogenesis might be different.

Substantial evidence has suggested that other adipokines, such as leptin and resistin are also involved in regulating disease progression of RA. Deng et al. have shown a function of leptin in enhancing Th17 cell response and exacerbating joint inflammation in CIA mice. In addition, resistin levels are found to be higher in the serum and synovial fluid of RA patients than in those with osteoarthritis (OA). The observed statistically significant correlation between synovial fluid resistin levels and rheumatoid factor (RF), anti-citrullinated protein/peptide autoantibody (ACPA) and Larsen score which further indicate that locally produced adipokines are closely implicated in synovial inflammation during the pathogenesis of RA.

In summary, our studies have demonstrated that AD can promote the differentiation of naïve T cell to Th17 cell and upregulate RANKL/OPG ratio, resulting in an enhanced synovitis and bone erosion in CIA models. These findings reveal a novel role of AD in mediating the development of autoimmune arthritis in mice. More clinical studies are needed to further confirm the potential therapeutic effect of targeting AD in the treatment of RA.

Figure 5. Local AD injection increases RANKL expression in joint tissue of CIA. (A,B). Immunohistochemical staining of RANKL in joint tissue of AD-treated and PBS-treated CIA mice on day 45 post the 1st immunization (magnifications: 200 × and 400 ×). RANKL-expressing cells were stained with intense brown color (n = 3). (C). Relative RANKL mRNA levels in joint tissue of AD-treated and PBS-treated CIA mice on day 45 post the 1st immunization (n = 7). All data were shown as mean ± SEM (*p < 0.05, ***p < 0.001). Results are derived from 3 separate experiments.
Methods

Ethics statement. All experiments were conducted in compliance with the guidelines for the care and use of laboratory animals and approved by Institutional Animal Care and Use Committee of Nanjing Medical University (Permit Number: IACUC-2013090101).

Experimental animals. Eight- to twelve-week-old DBA/1J mice were purchased from the Shanghai Laboratory Animal Center. Mice were fed under pathogen-free conditions at experimental animal center of Nanjing Medical University. All experiments were conducted according to the animal care and use committee guidelines.

CIA induction and AD treatment. CIA mice were induced as previously described. Firstly, 100μg of bovine type II collagen (CII) (Chondrex) was dissolved in 0.05 M acetic acid with an equal volume of Freund's complete adjuvant (Difco). Then DBA/1J mice were intradermally administered at the base of tail. On Day 21, booster injections were administered with 75μg of type II collagen and Freund's incomplete adjuvant (Difco) near the primary injection site. CIA mice were intraarticularly injected with AD (10μg AD in 10 μl PBS) into knee joints on day 17, day 20 and day 23 post first CII-immunization. Other CIA mice were treated with same volume of PBS as controls. CIA mice were scored for joint inflammation every day post 2nd CII-immunization, with a maximum arthritis severity score of 16 per mouse. Severity of disease was evaluated by visual inspection of the paws. Each paw was scored for the degree of inflammation on a scale from 0 to 4: 0, no evidence of erythema and swelling; 1, erythema and mild swelling confined to the midfoot (tarsals) or ankle joint; 2, erythema and mild swelling extending from ankle to the midfoot; 3, erythema and mild swelling extending from ankle to metatarsal joints; 4, erythema and severe swelling encompassing the ankle, foot, and digits. Scores from all four paws were added to give the total for each animal.
Cell culture. Purified naïve T cells (CD4⁺CD62L⁺ T cells) from C57 BL/6 mice were isolated by CD4⁺CD62L⁺ T Cell Isolation Kit II (Miltenyi) according to the manufacturer's instructions and the purity was >94%. Naïve T cells were cultured in 10µg/ml of anti-CD3 mAb and 3µg/ml of anti-CD28 mAb precoated in 24-well plates, and then 30ng/ml of IL-6 (R&D Systems), 30ng/ml of IL-23 (R&D Systems) and 3ng/ml of TGFB-β (R&D Systems) were added into the culture system in the presence of AD (1 and 10µg/ml) (R&D Systems) or without AD for 72 hours to induce Th17 differentiation. It had been confirmed that the endotoxin level of AD is <1.0 EU per 1µg of the protein by the limulus amebocyte lysate (LAL) method.

Flow cytometric analysis. Single-cell suspensions from mouse spleen and joint tissues were prepared. All samples were treated according to the manufacturer's recommendations. Anti-CD4, anti-CD3 and anti-IL-17 were used for Th17 cell surface markers staining, they were purchased from BioLegend. In order to perform intracellular staining for IL-17, phorbol myristate acetate (PMA), ionomycin and brefeldin (BFA) (Sigma) were added into the culture system for 5 hours before analysis.

RNA extraction and real-time PCR analysis. Cells and joint tissues were collected for real-time PCR analysis. RNA samples were extracted by Trizol reagent (Invitrogen) and then RNA was converted to complementary deoxyribonucleic acid (cDNA) using Prime Script™ RT regent Kit according to the manufacturer's instructions (Takara). PCR primers used for real-time PCR were as follows: for IL-17, sense 5'-CTTCACACAGGACACAGTG-3', antisense 5'-CTCCCTTCAGCTCATTTTCG-3'; for ROR-γt, sense 5'-CAAGAAGCGCTTCTGTCTCT-3', antisense 5'-GGTCAAGCTTCCACGACTGCT-3'; for IL-21, sense 5'-GGTCAAGCTTCCACGACTGCT-3', antisense 5'-GGAAGCGCTTCTGTCTCTCT-3'; for IL-23, sense 5'-CAGGCTTCTTTCAAGATCTCT-3', antisense 5'-ACTAAGGCTCAGTCAGGTTG-3'; for IL-22, sense 5'-TCCTCCCACTTTATG-3', antisense 5'-CCCCATGAGCCGACAT-3'; for IL-23, sense 5'-CAGGCTTCTTTCAAGATCTCT-3', antisense 5'-ACTAAGGCTCAGTCAGGTTG-3'; for AD, sense 5'-GGATGTTTTCGTGAGTGAGG-3', antisense 5'-GCGACTCCTGGATATAGAGG-3'; for RANKL, sense 5'-CAGGCTTCTTTCAAGATCTCT-3', antisense 5'-CTCGGTGTATCCATGACTCTCA-3'; for β-actin, sense 5'-TGTCACCCTCCAGCAGATGT-3', antisense 5'-AGCTCAGTACAGGCGCTTAG-3'. The real-time PCR analysis was detected by an ABI 7900 system (Applied BioSystems Inc) and the cycling parameters were as follows: 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Relative expression of target genes were calculated as 2^(-ΔΔCt).

Enzyme linked immune sorbent assay (ELISA). Levels of IL-17 in the culture supernatants were measured by ELISA (R&D Systems) according to the manufacturer’s recommendations. Briefly, serum samples (1: 5 dilution) and standards were added to the 96-well plates. After incubation for 2hours and washing 5 times, mouse IL-17 conjugate was added, followed by incubation with TMB substrate solution and stop solution. The intensity of the color reaction was measured by a microplate reader at a wavelength of 450 nm. Concentrations of IL-17 were determined by a standard curve according to the manufacturer’s instructions.

Haematoxylin & eosin (H&E) staining and immunohistochemical analysis. Paw and knee joints of CIA mice were removed from sacrificed mice for H&E staining and immunohistochemical analysis. Samples from each group were fixed in 4% buffered paraformaldehyde, decalcified in 50 mM ethylene diamine tetraacetic acid (EDTA). Then tissues were sectioned to 3μm thickness, deparaffinized in xylene and rehydrated through a series of concentrations of ethanol. The sections were prepared sagittal and stained with H&E and after inactivation of endogenous peroxidase, sections were blocked by incubation with 5% bovine serum album for 30 minutes at room temperature, then incubated with rabbit anti-human RANKL antibody (Abcam) diluted 1:50 at 4°C overnight in a humidified chamber. After washing, sections were next incubated with peroxidase-conjugated goat anti-rabbit secondary antibody for 1 hour at room temperature. The reactions were developed using a DAB substrate kit, with hematoxylin as counterstain. Each slide was evaluated by one of the authors under a microscope (Nikon). Tissue sections were scored for staining of the lining on a 0 to 5 scale as follows: 0, no staining; 1, few of the cells positively stained; 2, some (fewer than half) of the cells stained; 3, approximately half of the cells stained; 4, more than half of the cells stained; and 5, all cells stained. For each section, the number of positively stained cells was counted in 20 fields.

Micro-CT. Computed tomographic images of the knee joints and paws of the mice in all three groups (n = 3) were acquired on day 45 post the 1st immunization, using a Micro-CT Scan SkyScan1176S scanner at a resolution of 9μm. For verification of bone destruction, 3-dimensional models of the knee joints and paws were reconstructed using SkyScan CT Analyzer version 1.8. BMD were assessed by scanner software (Skyscan CTAn).

Statistical analysis. Data are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using one-way analysis of variance (ANOVA) tests. Results are derived from 3 separate experiments. The values of p<0.05 were considered significant.
References

1. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 365, 2205–2219 (2011).
2. Upchurch, K. S. & Kay, J. Evolution of treatment for rheumatoid arthritis. *Rheumatology (Oxford)* 51 Suppl 6, vi28–36 (2012).
3. Cohen, G. et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. *Ann Rheum Dis* 66, 358–363 (2007).
4. Andersen, M. et al. Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks: a cross-sectional study. *Arthritis Res Ther* 16, 1107 (2014).
5. Schett, G. & Gravallese, E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. *Nat Rev Rheumatol* 8, 656–664 (2012).
6. Versini, M., Jeandel, P. Y., Rosenthal, E. & Shoenfeld, Y. Obesity in autoimmune diseases: Not a passive bystander. *Autoimmun Rev* 13, 981–1000 (2014).
7. Kerekes, G. et al. Rheumatoid arthritis and metabolic syndrome. *Nat Rev Rheumatol* 10, 691–696 (2014).
8. Chen, X. et al. Adiponectin: a biomarker for rheumatoid arthritis? *Cytokine Growth Factor Rev* 24, 83–89 (2013).
9. Tan, W. et al. High adiponectin and adiponectin receptor 1 expression in synovial fluids and synovial tissues of patients with rheumatoid arthritis. *Semin Arthritis Rheum* 38, 420–427 (2009).
10. Mangge, H. et al. Inflammation, adiponectin, obesity and cardiovascular risk. *Curr Med Chem* 17, 4511–4520 (2010).
11. Frommer, K. W. et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis? *Ann Rheum Dis* 71, 1724–1732 (2012).
12. Meyer, M. et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. *Arthritis Res Ther* 15, B210 (2013).
13. Kato, H., Endres, I. & Fox, D. A. The roles of IFN-gamma versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. *Mod Rheumatol* 23, 1104–1110 (2013).
14. Li, G. et al. Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-kappaB/HIF-1alpha pathway. *Mol Immunol* 53, 227–236 (2013).
15. Chabaud, M., Fossiez, F., Taupin, J. L. & Moiseec, P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. *J Immunol* 161, 409–414 (1998).
16. Kikuta, J. & Ishii, M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. *Rheumatology (Oxford)* 52, 226–234 (2013).
17. Boyce, B. F. & Xing, L. Biology of RANK, RANKL, and osteoprotegerin. *Rev Drug Discov* 11, 401–419 (2012).
18. Truchetet, M. E., Allanore, Y., Montanari, E., Chizzolini, C. & Brembilla, N. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis. *Ann Rheum Dis* 71, 2044–2050 (2012).
19. Paulissen, S. M. et al. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxgenenase/prostaglandin E2 pathway, independent of IL-23. *J Immunol* 191, 1364–1372 (2013).
20. Iovancevic, D. V. et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. *J Immunol* 160, 3513–3521 (1998).
21. Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. *Arthritis Rheum* 42, 963–970 (1999).
22. Zwerina, K. et al. Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. *Eur J Immunol* 42, 413–423 (2012).
23. Moiseec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and type 17 helper T cells. *N Engl J Med* 361, 888–898 (2009).
24. Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory helper T helper cells. *Cell* 126, 1121–1133 (2006).
25. McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain TH(17)-cell-mediated pathology. *Nat Immunol* 8, 1390–1397 (2007).
26. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol* 7, 429–442 (2007).
27. Kedka, E. et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. *J Clin Invest* 114, 475–484 (2004).
28. Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. *Dev Cell* 3, 889–901 (2002).
29. Lacey, D. L. et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. *Nat Rev Drug Discov* 11, 401–419 (2012).
30. Adamopoulos, I. E. et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. *Arthritis Res Ther* 12, R29 (2010).
31. Kim, K. W. et al. Interleukin-22 Promotes Osteoclastogenesis in Rheumatoid Arthritis Through Induction of RANKL in Human Synovial Fibroblasts. *Arthritis Rheum* 64, 1015–1023 (2012).
32. Lee, S. W., Kim, J. H., Park, M. C., Park, Y. B. & Lee, S. K. Adiponectin mitigates the severity of arthritis in mice with collagen-induced arthritis. *Scand J Rheumatol* 37, 260–268 (2008).
33. Klaus, W. F. et al. Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis. *Ann Rheum Dis* 71, 1724–1732 (2012).
34. Piccio, L. et al. Lack of adiponectin leads to increased lymphocyte activation and increased disease severity in a mouse model of multiple sclerosis. *Eur J Immunol* 43, 2089–2100, (2013).
35. Deng, J. et al. Leptin exacerbates collagen-induced arthritis via enhancement of Th17 cell response. *Arthritis Rheum* 64, 3564–3573 (2012).
36. Fadda, S. M. H., Gamal, S. M., Elsaid, N. Y. & Mohy, A. M. Resistin in inflammatory and degenerative rheumatologic diseases relationship between resistin and rheumatoid arthritis disease progression. *Z Rheumatol* 72, 594–599 (2013).
37. Lo, C. K. et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. *Arthritis Rheum* 58, 2700–2711 (2008).

Acknowledgement

Funding: This study was supported by National Natural Science Foundation of China (NSFC) (81172845, 81273294, 81401352, 81302575, and 81302574), the special project of clinical medicine from Jiangsu Province (BL2013034), National Science Foundation of Jiangsu province (BK2011851, BK2012875, and BK20131028).
Author Contributions
Study concept and design: M.Z., W.T., N.Li. and X.S.; Acquisition of data: M.Z., W.T., X.S., X.F., N.Lin., M.H., Y.W. and F.W.; Analysis and interpretation of the data: M.Z., W.T. and X.S.; Write the paper: M.Z., X.S. and W.T. All authors reviewed the manuscript before submission.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Sun, X. et al. Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression. Sci. Rep. 5, 11296; doi: 10.1038/srep11296 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/